Follow the Hikal Limited share price and the full directors' dealings record of the company, a publicly traded company based in India. Shares are quoted on the IN market, under the authority of SEBI (PIT + SAST). Operating in the Health Care sector, Hikal Limited has recorded 10 insider filings. Market capitalisation: €26.9bn. The latest transaction was disclosed on 18 February 2026 (Purchase). Among the most active insiders: Ashok Vishwanath Hiremath. Every trade is openly available.
10
Insider Decl.
n/a
Thresholds
€2m
8 ops.
Buy Volume
€577,913
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Hikal Limited Strong Buy (bullish), based on 1 analysts. Average price target: ₹300.00.
19Σ signal
Buys €2m€577,913 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,150 of 28,717 companies
38.2
score / 100
Value
38
Quality
38
FCF yld5.7%
Earn yld-1.8%
EV/EBITDA22.8x
ROE·
Gross mgn55%
Net mgn-2.9%
Debt/EBITDA4.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
15,000 shares@ ₹354.876215.0% of flowEquity SharesSEBI:9748e4072446120a0e51f9cec181435eba617482
10 of 10 declarations
About Hikal Limited
Hikal Limited is a company operating in the healthcare and pharmaceutical sector, specializing in the manufacturing of chemicals and pharmaceuticals. It is listed on the XBOM market.